drugset
drugset / Trial / NCT04403529

Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

NCT04403529 ↗

Phase 3 Unknown 200 enrolled Fudan University
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a prospective, single site, randomized, double-blind Phase III clinical trial to evaluate the clinical value of Traditional Chinese Medicine in the adjuvant therapy of triple-negative breast cancer patients.

Timeline

Start
2020-05-25
Primary completion
2024-05-31
Completion
2024-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Traditional Chinese Medicine Formulation Traditional medicine (herbal / TCM) — Oral

Indications

triple-negative breast carcinoma